# Safety and Tolerance of Increased Doses of HRS-5346 Tablets in Healthy Subjects

> **NCT06441227** · PHASE1 · COMPLETED · sponsor: **Shandong Suncadia Medicine Co., Ltd.** · enrollment: 71 (actual)

## Conditions studied

- Lipoprotein Disorder Disease

## Interventions

- **DRUG:** HRS-5346 tablets
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT06441227
- **Lead sponsor:** Shandong Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-13
- **Primary completion:** 2025-01-09
- **Final completion:** 2025-01-09
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06441227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06441227, "Safety and Tolerance of Increased Doses of HRS-5346 Tablets in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06441227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*